Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Metastatic HER2-Positive Breast Cancer Market Expected to Surge at a CAGR of 8.3% During the Forecast Period (2026–2036) Due to Advancing Targeted Treatments | DelveInsight

globenewswire.com
PFE Pfizer's drug IBRANCE (palbociclib) is mentioned as a current treatment option for metastatic HER2-positive breast cancer. The company is also listed among key PROTAC companies, indicating potential future involvement in this therapeutic area. JNJ Johnson & Johnson's acquisition of Ambrx Biopharma is highlighted as a strategic move to strengthen its capabilities in targeted oncology therapies, suggesting a positive outlook for its involvement in this market segment. AMRX Ambrx's HER2-targeted ADC, ARX788, is under assessment in clinical trials. While the company itself was acquired by Johnson & Johnson, its drug development is noted as progressing. BOLT Bolt Biotherapeutics is mentioned for its drug BDC-1001 ± pertuzumab, indicating its participation in the development of treatments for metastatic HER2-positive breast cancer. BIIB BioInvent International AB is mentioned for its drug BI-1607 + Trastuzumab, indicating its involvement in the development of targeted therapies for metastatic HER2-positive breast cancer.

Metastatic HER2-Positive Breast Cancer Market Expected to Surge at a CAGR of 8.3% During the Forecast Period (2026–2036) Due to Advancing Targeted Treatments | DelveInsight New York, USA, June 01, 2026 (GLOBE NEWSWIRE) -- Metastatic HER2-Positive Breast Cancer Market Expected to Surge at a CAGR of 8.3% During the Forecast Period (2026–2036) Due to Advancing Targeted Treatments | DelveInsight

The metastatic HER2-positive breast cancer market outlook continues to be promising, supported by ongoing innovation, expanding therapeutic indications, lifecycle management initiatives, and increasing demand for more effective and patient-friendly HER2-targeted treatments, including SYD985 (trastuzumab duocarmazine) (Byondis), Giredestrant (Roche), ARX788 (Ambrx), IBRANCE (palbociclib) (Pfizer), BDC-1001 ± pertuzumab (Bolt Biotherapeutics), BI-1607 + Trastuzumab (BioInvent International AB), and others.

Recently published Metastatic HER2-positive Breast Cancer Market Insights report includes a comprehensive understanding of current treatment practices, metastatic HER2-positive breast cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Metastatic HER2-positive Breast Cancer Market Summary

Discover what is the future of metastatic HER2 breast cancer treatment market @ https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-market

Key Factors Driving the Growth of the Metastatic HER2-positive Breast Cancer Market

According to Aparna Thakur, an oncology expert at DelveInsight, as promising novel anti-HER2 treatments emerge, the field will continue to revolutionize, with guidelines beginning to include novel treatment options in the third-line setting and thereafter.

Metastatic HER2-positive Breast Cancer Market Analysis

Learn more about which HER2 therapy will dominate first-line metastatic setting @ Metastatic HER2-positive Breast Cancer Treatment Market

Metastatic HER2-positive Breast Cancer Competitive Landscape

Some of the metastatic HER2-positive breast cancer drugs under development include SYD985 (trastuzumab duocarmazine) (Byondis), Giredestrant (Roche), ARX788 (Ambrx), IBRANCE (palbociclib) (Pfizer), BDC-1001 ± pertuzumab (Bolt Biotherapeutics), BI-1607 + Trastuzumab (BioInvent International AB), and others.

Byondis’ SYD985 (trastuzumab duocarmazine) is an ADC composed of the monoclonal antibody trastuzumab linked to a cleavable payload, valine-citrulline-seco-DUocarmycin-hydroxyBenzamide-Azaindole (vc-seco-DUBA). In May 2023, the US FDA issued a Complete Response Letter (CRL) for the biologics license application of vic-trastuzumab duocarmazine (SYD985), which was being evaluated for the treatment of patients with HER2-positive unresectable, locally advanced, or metastatic breast cancer.

Ambrx’s ARX788, another HER2-targeted ADC, is being assessed across several clinical trials for breast cancer, gastric/gastroesophageal junction (GEJ) cancer, and other solid tumors. The therapy is currently undergoing Phase II/III studies for HER2-positive metastatic breast cancer and gastric cancer. In March 2024, Johnson & Johnson announced the successful acquisition of Ambrx Biopharma. Through this acquisition, Johnson & Johnson aims to strengthen its capabilities in the development and commercialization of targeted oncology therapies.

The anticipated launch of these emerging metastatic HER2-positive breast cancer therapies are poised to transform the metastatic HER2-positive breast cancer market landscape in the coming years. As these cutting-edge metastatic HER2-positive breast cancer therapies continue to mature and gain regulatory approval, they are expected to reshape the metastatic HER2-positive breast cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about upcoming HER2 metastatic breast cancer drugs, visit @ Metastatic HER2-positive Breast Cancer Medication

Recent Developments in the Metastatic HER2-positive Breast Cancer Market

What is Metastatic HER2-positive Breast Cancer?

Metastatic HER2-positive breast cancer is an advanced form of breast cancer in which tumor cells overexpress the human epidermal growth factor receptor 2 (HER2), a protein that promotes rapid cancer cell growth and proliferation. In this stage, the cancer has spread beyond the breast and nearby lymph nodes to distant organs such as the bones, liver, lungs, or brain. HER2-positive disease accounts for approximately 15–20% of all breast cancer cases and is generally associated with aggressive tumor behavior and a higher likelihood of recurrence. However, the development of targeted therapies, including HER2-directed monoclonal antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors, has significantly improved survival outcomes and disease management for patients with metastatic HER2-positive breast cancer.

Metastatic HER2-positive Breast Cancer Epidemiology Segmentation

The metastatic HER2-positive breast cancer epidemiology section provides insights into the historical and current V patient pool and forecasted trends for the leading markets. The metastatic HER2+ breast cases were highest in the treatment-eligible pool for HER2+ breast cancer in the US, accounting for ~14,500 cases.

The metastatic HER2-positive breast cancer market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

Download the report to understand which therapies will dominate HER2+ metastatic breast cancer market @ Metastatic HER2-positive Breast Cancer Treatment Options

Scope of the Metastatic HER2-positive Breast Cancer Market Report

Discover more about next-generation HER2 therapies @ Metastatic HER2-positive Breast Cancer Clinical Trials

Table of Contents

Related Reports

Metastatic HER2-Positive Breast Cancer Clinical Trial Analysis

Metastatic HER2-Positive Breast Cancer Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic HER2-positive breast cancer companies, including Byondis, Roche, Ambrx, Zymeworks, Jazz Pharmaceuticals, Pfizer, and others.

SERD Market

SERD Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report deliver an in-depth understanding of the market share of the individual therapies, and key SERD companies including Stemline Therapeutics, Roche, AstraZeneca, Eli Lilly, and others.

PROTAC Market

PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key PROTAC companies, including Arvinas, Pfizer, BMS, Hinova Pharmaceuticals, Accutar Biotech, Nurix Therapeutics, Dialectic Therapeutics, Kymera, Sanofi, and others.

Metastatic HR+/HER2− Breast Cancer Market

Metastatic HR+/HER2− Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key breast cancer companies including Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, and others.

ESR1 Mutated Metastatic Breast Cancer Market

ESR1 Mutated Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ESR1 mutated metastatic breast cancer companies, including Roche, Genentech, AstraZeneca, Olema Pharmaceuticals, Sermonix Pharmaceuticals, Kind Pharmaceuticals, Eisai, Stemline Therapeutics (Menarini Group), Eli Lilly and Company, Arvinas, Pfizer, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.